
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 March 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 5MB, 224 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
“Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis”, Calcif Tissue Int, vol. 97, pp. 104-12, 2015.
, “Individuals With Type 2 Diabetes Mellitus Are at an Increased Risk of Gout But This Is Not Due to Diabetes: A Population-Based Cohort Study”, Medicine (Baltimore), vol. 94, p. e1358, 2015.
, “Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients”, Br J Clin Pharmacol, vol. 80, pp. 1464-72, 2015.
, “Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study”, Diabetes Obes Metab, vol. 19, pp. 421-428, 2017.
, “Risk of community-acquired pneumonia in chronic obstructive pulmonary disease stratified by smoking status: a population-based cohort study in the United Kingdom”, Int J Chron Obstruct Pulmon Dis, vol. 12, pp. 2425-2432, 2017.
, “Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study”, Bmj, vol. 354, p. i3625, 2016.
, “Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture”, Bone, vol. 68, pp. 124-30, 2014.
, “Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study”, PLoS One, vol. 10, p. e0139367, 2015.
, “Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study”, Diabetes Obes Metab, vol. 19, pp. 401-411, 2017.
, “Use of incretin agents and risk of pancreatic cancer: a population-based cohort study”, Diabetes Obes Metab, vol. 18, pp. 258-65, 2016.
,